Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Influenza research Stories

2011-07-18 11:00:00

GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune announced today that it has begun shipping FluMist® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States. MedImmune expects to provide approximately 15 -16 million doses of its trivalent (three-strain) nasal spray flu vaccine for the 2011-2012 influenza season through a variety of private health care practices, public health...

2011-07-18 07:58:00

SWIFTWATER, Pa., July 18, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it began shipping its 2011-2012 Fluzone® Influenza Virus Vaccine in the U.S. This shipment represents the first of approximately 70 million doses of seasonal influenza vaccine the company plans to deliver to the U.S. in the upcoming season. "As the largest producer of influenza vaccine in the U.S., supplying more than 40...

b08b450dda0171725fc3c0d5739d4c25
2011-07-15 07:45:00

The United Nations' World Health Organization said on Thursday that worldwide production of seasonal flu vaccine is expected to double to 1.7 billion doses by 2015, with eleven new manufacturers ramping up in developing nations, Reuters reports. Furthermore, in the event of a new influenza pandemic, a projected 37 vaccine makers could potentially triple their annual production of trivalent seasonal vaccine to produce some 5.4 billion doses, the U.N. agency said. However, experts say the...

2011-07-07 03:00:00

BLUE BELL, Pa., July 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory...

2011-06-13 07:51:01

(Ivanhoe Newswire) -- In a new research article, Harvard scientists outline a variety of factors that influence vaccine production and access to those vaccines. Researchers say the technologies used to manufacture different types of vaccines affect cost and availability. Other factors such as different national regulations, shelf life, and cold chain requirements may also influence vaccine cost. For example, the researchers say the oral polio vaccine strains grow well in culture, which allows...

27a9e6dab4eb5b5173e479ad14868a9f
2011-06-09 05:05:00

The need to create a new flu vaccine annually could be eliminated with a universal influenza vaccine that targets a protein common to all strains of influenza A, which has been able to safely produce an immune response in humans, according to a study published in the journal Vaccine. If proven effective, it will have major implications for global health. Two studies were conducted, one at the University of Texas Medical Branch at Galveston (UTMB) and one at Johnson County Clin-Trials in...

2011-06-07 08:10:00

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States. "This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same...

2011-05-10 07:00:00

SWIFTWATER, Pa., May 10, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine). Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and...

2011-05-09 07:00:00

ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011. The company reported a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011, compared to a net loss of $10.3 million, or $0.10 per share, for the first quarter of 2010. The primary reason for the decreased loss during the quarter was due to lower research and development spending to support clinical trials of the...

2011-04-29 11:00:00

-largest livestock vaccine manufacturing facility in Canada- BELLEVILLE, ON, April 29 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX:BNC) (ASX:BNC), a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada. This facility represents the largest livestock vaccine manufacturing facility in Canada, with capacity to supply...